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Abstract
Introduction: Nicotine addiction has become one of the largest international health problems, increasing the
risk of cardiovascular disease, cancers, and respiratory diseases. There are several treatments available for
smoking cessation with the most common transdermal nicotine replacement and anti-depressants. However
current treatments are only mildly efficacious and have side effects which lead to a decrease in their
effectiveness. Additional treatments for smoking cessation with lower side effects are required. Methods: We
examined the efficacy of Remotiv® (Hypericum perforatum Special Extract - ZE117) compared to Nicabate®
CQ Nicotine Replacement Therapy (NRT) and combination ZE117/NRT for smoking cessation over a
treatment time of 10 weeks. Given the different pharmacological profiles of Ze117 and NRT it was expected
that a combination treatment would be most efficacious for smoking cessation than the other two treatments
alone. Sixty smokers aged between 18 and 60 years were enrolled in the study. Smoking status was assessed
using CO levels measured by the Bedfont Smokerlyzer (primary outcome measure). Secondary outcome
measures of anxiety, DSMIV nicotine dependence and Fagerström craving and symptoms were also recorded.
Results: A significant main effect of reduction in the number of smokers over the course of the study was
observed although there were no significant differences between any of the treatment groups on this variable
after 14 weeks. Conclusions: These results indicate that the three treatment options are equally efficacious for
smoking cessation. Interestingly the Ze117 treatment significantly reduced the amount of craving over the
treatment duration of the study compared to the other two treatments indicating a possible mechanism by
which Ze117 may assist in smoking cessation.
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Introduction
Nicotine addiction has become one of the largest international 
health problems, increasing the risk of life threatening diseases. It is 
estimated that smoking causes an alarming 22% of cardiovascular 
disease, 30% of all cancers, 70-90% of lung cancers and 56-80% of 
respiratory diseases [1]. With 21% of the Australian adult population 
classed as regular smokers, cigarette smoking has been reported to 
be responsible for 19,000 Australian deaths each year [2]. Smoking-
related illnesses contribute significantly to healthcare costs and pose 
a considerable burden on the healthcare system and are estimated to 
cost the Australian community $21 billion dollars annually [3]. Even 
for those who choose to quit smoking, cessation may be difficult and 
is often unsuccessful. Community quit rates for smokers attempting to 
quit without pharmacological treatment or supportive counselling have 
been reported as 17% [4], which should be seen as unacceptably low 
given the negative health consequences of smoking.
Drugs of addiction exert influence over the brain reward pathway 
[5]. It is thought that dopaminergic stimulation of the nucleus 
accumbens reinforces use of the drug [6]. Addictive drugs may either 
directly influence the action of the neurotransmitter dopamine, or alter 
the activity of other neurotransmitters that exert a modulatory influence 
over the mesolimbic dopaminergic pathway [5]. Gamma aminobutyric 
acid (GABA), opioid, serotonergic, cholinergic and noradrenergic 
neurotransmitter pathways have all been shown to interact at various 
points along the mesolimbic dopaminergic pathway and to modulate 
its activity [7]. 
As one of the most addictive drugs of abuse, nicotine exerts direct 
influence on nicotinic acetylcholine (ACh) receptors located on the 
cell bodies of dopamine neurons within the ventral tegmental area 
(VTA) [8]. Activation of these nicotinic ACh receptors increases the 
action of dopamine neurons, resulting in stimulation of the nucleus 
accumbens [9,10]. Additionally, nicotinic receptors located on other 
neurotransmitter inputs to the VTA may further increase dopamine 
release by removing the inhibitory influence of other neurotransmitters 
(i.e. decrease GABA and increase Glutamate [7,8].
The biology of nicotine addiction has also been found to be linked 
to changes in serotonergic transmission associated with chronic use 
[11]. Acute smoking has been found to increase serotonin release, 
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Abstract
Introduction: Nicotine addiction has become one of the largest international health problems, increasing 
the risk of cardiovascular disease, cancers, and respiratory diseases. There are several treatments available for 
smoking cessation with the most common transdermal nicotine replacement and anti-depressants. However current 
treatments are only mildly efficacious and have side effects which lead to a decrease in their effectiveness. Additional 
treatments for smoking cessation with lower side effects are required. 
Methods: We examined the efficacy of Remotiv® (Hypericum perforatum Special Extract - ZE117) compared 
to Nicabate® CQ Nicotine Replacement Therapy (NRT) and combination ZE117/NRT for smoking cessation over a 
treatment time of 10 weeks. Given the different pharmacological profiles of Ze117 and NRT it was expected that a 
combination treatment would be most efficacious for smoking cessation than the other two treatments alone. Sixty 
smokers aged between 18 and 60 years were enrolled in the study. Smoking status was assessed using CO levels 
measured by the Bedfont Smokerlyzer (primary outcome measure). Secondary outcome measures of anxiety, DSM-
IV nicotine dependence and Fagerström craving and symptoms were also recorded. 
Results: A significant main effect of reduction in the number of smokers over the course of the study was 
observed although there were no significant differences between any of the treatment groups on this variable after 
14 weeks. 
Conclusions: These results indicate that the three treatment options are equally efficacious for smoking 
cessation. Interestingly the Ze117 treatment significantly reduced the amount of craving over the treatment duration 
of the study compared to the other two treatments indicating a possible mechanism by which Ze117 may assist in 
smoking cessation.
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while chronic smoking decreasing the concentration and synthesis of 
brain serotonin [12]. An increase in serotonin transporter density in 
the prefrontal cortex has also been found to be associated with chronic 
nicotine administration [13,14] . During nicotine withdrawal there 
appears to be an increased sensitivity of serotonin neurons in the dorsal 
raphe nucleus [15].
Current pharmacological methods for treating smoking addiction 
in Australia that are approved by the government regulator include 
Nicotine Replacement Therapy (NRT) and Bupropion [16]. In the 
USA, the Food and Drug Administration (FDA) have approved a 
number of Nicotine Replacement Therapies including nicotine patches, 
gum, lozenges, sprays and inhalers [17]. There have also been two 
other pharmacological treatments approved by the FDA: Varenicline 
and Buproprion [18]. Randomised trials have found Buproprion to be 
effective in assisting cessation of smoking. Hurt et al., [19] reported 
the seven week quit rate for Bupropion to be significantly greater 
than the placebo quit rate of 19%. While Bupropion has been shown 
to be effective in the management of smoking cessation, there are 
significant adverse effects associated with its use including seizures, 
insomnia, dizziness, headache and skin reactions [16]. Although not 
substantiated by research, there have been anecdotal reports of sudden 
death associated with Bupropion Two randomised controlled trials 
have reported that 12 weeks treatment with Varenicline to be more 
effective than Bupropion in the maintenance of continuous abstinence 
rates during weeks 9 to 24 after quit date [20-22]. Quit rates associated 
with Varenicline were reported to be 44% and 43.9%, while quit rates 
associated with Bupropion were 29.5% and 29.8%, and quit rates 
for placebo were 14% and 17.7% [20-22]. A number of adverse side 
effects associated with Varenicline use were reported in these studies, 
including nausea, headache, insomnia and abnormal dreams [20-22]. 
Discontinuation of treatment due to adverse events occurred in 8.6% 
and 10.5% of recipients in the Varenicline group and 15.2% and 12.6% 
in the Bupropion group compared to 9.0% and 7.3% of participants in 
the placebo group [20-22]. Gonzales et al., [20] reported two serious 
adverse events attributed to the study treatment: an episode of atrial 
fibrillation was attributed to Varenicline and a grand mal seizure 
attributed to Buproprion. Jorenby et al., [21] also reported serious 
adverse effects including vertigo, hypertension and chest pain in a 
participant receiving Varenicline and angioedema in a Bupropion 
recipient.
Nicotine Replacement Therapy (NRT)
NRT assists in smoking cessation by providing a constant level 
of nicotine to prevent withdrawal effects [23] and has been reported 
to be safe and effective in relieving withdrawal symptoms associated 
with smoking cessation 24,25]. Delivery modes for NRT include 
Transdermal nicotine (TN), gum, sublingual tablets and oral inhalers 
[16]. In a meta-analysis of randomised trials, Silagy et al., [26] found 
no significant difference in cessation rates for different delivery modes, 
tapering of dose versus abrupt withdrawal and 12 week compared to 28 
week treatment [26]. Slowed delivery (i.e. sustained release) of nicotine 
using TN is considered the preferred form of NRT, as it has the lowest 
potential for addiction [27] TN is also considered to be the easiest form 
to use and has the lowest level of adverse effects [28,29]. 
Hays et al., [29] conducted a double-blind placebo controlled 
trial which compared the efficacy of six week treatment of daily 22mg 
nicotine patches (TN) compared to placebo. They also included an open 
label arm to compare the efficacy of the same therapy with participants 
purchasing their own patches. Smoking cessation rates were greater 
for TN (16.8%; 8.7%) in comparison to placebo (9.6%; 4.3%) in 
the controlled trial at weeks 6 and 24. There was a slight increase in 
cessation rates in the open label arm of the trial (19.0%; 10.8%) at weeks 
6 and 24 [29].
Adverse effects of NRT may be associated with delivery mode or 
the effects of the nicotine itself. Adverse effects that are specific to the 
mode of delivery include: nasal irritation and runny nose for nasal 
spray; coughing, throat irritation and oral burning for inhalation; skin 
rash for TN; jaw pain and hiccups from chewing the gum; dry lips, 
mouth ulcers and sore throat from sublingual tablets [30]. Nicotine 
related adverse effects associated with all modes of delivery include, 
dry mouth, nausea, headache and palpitations [16]. These side effects 
greatly contribute to the relatively low effect size of these delivery 
systems in smoking cessation trials.
Cochrane reviews have indicated that the effectiveness of all three 
treatments are relatively poor with a high degree of relapse at 6 months 
[17,31,32]. Clearly alternative treatments with lower side effects are 
urgently required for nicotine addiction. For some individuals a new 
treatment may be important after failing current treatments and 
therefore additional choice may be important. Additionally a new 
treatment may also be important if it is more cost effective than current 
treatments.
Hypericum perforatum and smoking cessation 
The pharmacological properties of Hypericum perforatum (HP) 
suggest a potential role in reducing addiction to nicotine. HP is the only 
antidepressant capable of inhibiting the reuptake of the monoamines: 
serotonin, noradrenaline and dopamine with similar potencies [33,34]. 
HP has previously been found to normalize dopaminergic as well 
as noradrenergic transmission in the medial PFC [35,36]. Recently 
Ruedeberg et al., [37] have argued for the use of HP in smoking 
cessation based on dopamine re-uptake in rat striatal cortex after 
HP administration. HP also inhibits the reuptake of amino acids and 
neurotransmitters GABA and glutamate [33,34] suggesting that HP 
both directly and indirectly influences the dopamine reward pathways. 
Preclinical research has provided evidence to suggest that chronic 
HP supplementation also enhances serotoninergic transmission in the 
PFC [38] and may be of benefit in counteracting the deleterious neural 
effects of chronic stress [39]. These findings are particularly relevant to 
individuals undergoing nicotine withdrawal, as smoking abstinence has 
been found to be associated with elevations in stress hormones [40]. 
With proven efficacy as an antidepressant for mild to moderate clinical 
depression [41,42], HP may also assist in cessation of smoking via 
reduction in depressive symptoms associated with nicotine withdrawal.
Although conventional anti-depressants have been shown to reduce 
the urges associated with nicotine withdrawal they have not been 
shown to be efficacious in abstinence [23]. Dopaminergic acting drugs 
however have been shown to decrease both the symptoms of nicotine 
withdrawal and abstinence rates but show significant side-effects. As 
Parsons et al., [43] have argued, because HP acts uniquely on both of 
these neurotransmitter systems it is important to directly test whether 
HP directly improves smoking abstinence. Certainly the side-effect 
profile of HP is significantly better than other treatments for smoking 
cessation. HP does not appear to have the anticholinergic effects 
(delirium, sedation, cognitive impairment) of other antidepressants 
[44] and the adverse effect profile of HP is extremely good compared to 
other antidepressants [41,42].
The potential benefit of HP on smoking cessation has been 
investigated in animal studies as well as preliminary clinical trials in 
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humans. Barnes et al., [45] conducted an open, uncontrolled pilot study 
to examine the effects of HP (LI-160) on smoking cessation. Twenty-
eight participants were administered 300mgor 600mg HP (equivalent 
to 900 mcg or 1800 mcg hypericin) daily, with treatment commencing 
one week prior to the quit date and continuing for 12 weeks after quit 
date. The abstinence rates at 3 months and 12 months after the quit date 
were 18% and 0% respectively for the combined HP treatment groups. 
Barnes et al., [45] concluded that the results did not provide convincing 
evidence for the efficacy of HP as an aid in smoking cessation. However 
there were a number of problems with this trial including the very 
small sample size, and a run-in period for HP that was too brief for 
the treatment to be effective. As with most antidepressants, four to six 
weeks of treatment is typically required to achieve therapeutic benefit 
[46]. 
Lawvere et al., [47] also examined the efficacy of a daily dose of 
900mg HP (equivalent to hypericin 2700 mcg) on cessation rates of 24 
smokers in an open-label trial. Treatment commenced a week before 
quit date and continued a further 12 weeks after quit date. Thirty-five 
percent of participants were found to be smoke free at 12 weeks after the 
quit date. Anxiety was also found to be significantly reduced from the 
third to the twelfth week after the quit date, and a decrease in depression 
scores and nicotine withdrawal symptoms was evident during the 12 
week course of the study [47]. Lawvere et al., [47] concluded that HP 
may prove to be a useful adjunctive therapy for smoking cessation.
In a more recent placebo controlled clinical trial Parsons et al., 
[43] examined the efficacy of 900mg HP daily (equivalent to hypericin 
1080-2520 mcg) versus placebo for 16 weeks. In a factorial design 
participants were also allocated chromium or placebo. There were 
no significant differences between the SJW and the placebo group 
at either 4 or 16 weeks indicating that the HP used in this study was 
not effective in smoking abstinence. Surprisingly there was also no 
significant difference in any of the mood related variables or urges to 
smoke between the HP and placebo groups indicating that the HP in 
this trial did not effectively increase serotononergic or dopaminergic 
activity which would have decreased nicotine cravings and negative 
moods. In a similar trial using another different HP extract, Sood et al., 
[48] administered 900 mg HP/day versus 1800 mg HP/day (equivalent 
to hypericin 2700 mcg and hypericin 5400 mcg) for 12 weeks in 118 
participants. Sood et al., [48] reported that there were no significant 
differences in abstinence rates between either of the HP groups or 
placebo at both12 or 24 weeks post-treatment.
In consideration of the strong preclinical evidence of central 
dopaminergic effects associated with HP [35,36], the mixed results 
of these human trials are hard to reconcile. One possible explanation 
for the different findings for each of these trials may be attributed to 
use of different HP extracts, with differences in quality across different 
manufacturers. Unlike pharmaceuticals in which an active compound 
is concentrated and reliably reproduced from batch to batch, a 
nutraceutical like HP may significantly differ for a number of factors 
including climatic conditions during growth, geographical location, 
extraction technique, as well as handling and transportation techniques.
Ze117 standardized Hypericum perforatum extract 
Ze 117 (Remotiv®) is a HP extract which has been widely tested for 
its safety and efficacy and has been clinically proven to be as effective 
as, and better tolerated than antidepressants in relieving depressive 
symptoms [49-51]. Ze 117 is a standardised product containing 1.375 
g HP herb, 500 mcg hypericin and negligible levels of hyperforin [52] 
which is the constituent believed responsible for interactions with other 
medications [53,54]. Ze 117 has been used in an estimated 6 million 
patients in the last 10 years, with an extremely low incidence of reported 
side effects in trials and in clinical use (Periodic Safety Update Report, 
Ze 117 March 2004).
A pilot study from our laboratory conducted in 2006 examined 
the effects of Ze117 HP extract (Ze117; 500mcg Hypericin 2/d) in the 
management of smoking cessation compared to a transdermal nicotine 
patch (Nicabate CQ; step down regime commencing at 24 mg/day) [55]. 
Forty Participants aged between 18 and 60 years who had smoked for 
at least 5 years and were wishing to quit smoking were enrolled in the 
study. The study was conducted over a 14 and 10 week administration 
period for the HP and NRT groups, respectively. The results of the 
study revealed that participants in both the HP (n=17) and NRT (n=12) 
groups decreased the number of cigarettes smoked per day over the 
12 week treatment period. Quit rates for the HP and TN groups were 
not statistically different indicating that there were equivalent numbers 
of smokers from both the HP and TN groups who were able to quit 
smoking.
The current study
The current study extended on the methodology of the initial 
pilot study from our laboratory, examining the efficacy of Hypericum 
perforatum (HP; ZE117) in the management of smoking cessation, both 
as monotherapy and as augmentation to Transdermal NRT for smoking 
cessation in a larger sample. Our outcome measure was abstinence 
rate (primary outcome variables) determined by CO measurement. 
Secondary outcome measures included the number of cigarettes 
smoked, cravings and withdrawal symptoms associated with smoking 
cessation. Given the similar pharmacological profile to Buproprion, 
it was hypothesized that there would be no difference in our primary 
outcome variable between the Ze117 or NRT groups. It was also 
hypothesized that combined Ze117/NRT would work more effectively 
than either NRT or Ze117 used in isolation. 
Clinical significance
The results may have significant benefits for influencing health 
promotion policies in Australia (and internationally) and may help 
encourage current smokers to attempt to quit either for the first time 
or after one or more failed attempts. If proven effective the cost of 
Ze117 is also highly advantageous in relative terms to other current 
treatments. Current treatments are only at best moderately effective. 
According to the American Cancer Society (Nov 2013) between 4 and 
7% of smokers are able to quit smoking after any attempt and only 
about 25% of smokers are able to successfully quit smoking with the 
help of current pharmaceutical interventions. Smokers who fail to quit 
smoking show significant negative effects on their quality of life, their 
health and the community by way of economic burden of caring for 
patients with cancer, coronary heart disease and other diseases due 




Sixty volunteers, aged between 18 and 60 years, were recruited to 
participate in the trial. All interested individuals were screened over the 
phone by the research officer to assess their suitability for participation 
in the study based on the following selection criteria: Smoking for 
at least 5 years and currently smoking at least 10 cigarettes per day, 
at least one prior attempt at quitting smoking, motivation to quit 
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smoking, weighing more than 45 kg, no history of anxiety/depression, 
not currently taking any prescription medications, no other chronic 
health conditions , not currently or in past 6 months taking HP or 
antidepressants, not currently or in past 6 months classified as being 
addicted to any substances apart from nicotine, not currently using 
NRT and not pregnant or lactating. Once deemed suitable to participate 
in the study participants committed to a quit date with the research 
officer and were booked in for their first testing session 4 weeks prior 
to their quit date. All testing was conducted at Swinburne University 
Hawthorn Campus. All participants provided informed consent to 
participate in the study which was approved by Swinburne University 
Human Research Ethics committee.
Study design
The study was conducted over a 14 week period at the Brain Sciences 
Institute at Swinburne University of Technology, Hawthorn. Following 
the first (baseline) visit, participants were randomly allocated to one 
of three treatment groups: Group 1-Hypericum perforatum (Ze117; 
500 mcg×2 daily), Group 2-Transdermal NRT (Nicabate CQ clear) 
and Group 3-Hypericum perforatum (Ze117; 500 mcg×2 daily) and 
Transdermal NRT (Nicabate CQ clear).
The primary endpoints were: (1) The mean number of smokers in 
each treatment group, as defined by a reading of ≥ 6 ppm on the Benfont 
Smokerlyzer at Visit 4, 10 weeks post quitting smoking. (2) Change in 
the mean number of cigarettes smoked per week in each treatment 
group at Visit 4, 10 weeks post quitting smoking in comparison to 
Baseline. The secondary endpoints were state anxiety measured by 
the State Trait Anxiety Inventory (STAI), DSM criteria for nicotine 
dependence & Fagerstrom dependence measures.
Investigational treatments
Remotiv® Ze117: Ze117 is a high quality standardized HP extract 
manufactured by Zeller (Switzerland) which contains 1.375 g HP herb 
and 500 mcg hypericin. Ze117 has clinically established safety and 
efficacy as an antidepressant [49-51]. As with most antidepressants, it 
takes four to six weeks administration of Ze117 to achieve therapeutic 
benefits [46]. Therefore, participants taking Ze117 commenced a wash-
in period (500mcg hypericin×2/d) of four weeks (28 days) prior to the 
quit date. Ze117 is sold in Australia by Flordis under the registered 
trademark Remotiv®.
Nicabate CQ (clear): It is an over the counter pharmaceutical and 
treatment consists of a ten week step down process consisting of three 
stages: Step 1: Weeks 1-5-Six weeks on a patch delivery of 21 mg nicotine 
over 24 hours; Step 2: Weeks 6-7-Two weeks on a patch delivering 14 
mg of nicotine over 24 hours; Step 3: Weeks 8-10-Two weeks on a 7 mg 
of nicotine delivery over 24 hours. 
Materials
Smoking abstinence was confirmed using The Bedfont Compact 
Smokerlyser (Bedfont instruments, Kent, UK). The Bedfont 
Smokerlyser measures carbon monoxide (CO) levels in the breath in 
parts per million (ppm). This measurement is based on the conversion 
of CO to CO2 over a catalytically active electrode. When the breath 
is held, equilibrium is established between CO in the blood and CO 
in alveolar air, therefore there is a high degree of correlation between 
breath CO levels and COHb concentration [56]. In the current study, a 
measurement of 6 ppm was taken as confirmation of the smoking status 
of participants. This is a more stringent cut-off value used by Parsons et 
al., [43] who used 10 ppm and Sood et al., [48] who used 8 ppm.
The Fagerström Test for Nicotine Dependence (FTND) [57] is an 
8-item self-report questionnaire, with a total score ≥ 7 indicative of 
high nicotine dependence. The State-Trait Anxiety Inventory (STAI) 
[58] is a self-report assessment device consisting of two parts: (i) State 
Anxiety, a 20-item scale measuring an individual’s transitory feelings 
of tension and apprehension, and (ii) Trait Anxiety, a 20-item scale 
measuring relatively stable individual differences in anxiety proneness. 
In this paper we report the state component of the STAI. 
Procedure
Participants were required to attend Swinburne University for an 
initial baseline visit 4 weeks prior to quitting cigarettes, then again for 
a retest at week 4 (quit date), week 10 (6 weeks post quit) and week 14 
(10 weeks post quit). 
Visit 1: Baseline visit Pre-quit (Week 0): Participants visited 
Swinburne University 4 weeks prior to their quit date for the first 
testing session. During this first visit, participants completed a general 
questionnaire regarding their health, demographics, vitals (blood 
pressure, pulse rate), educational and social economic status, and 
smoking habits. During each testing session the following assessments 
were administered: the Fagerström Test for Nicotine dependence 
(FTND) as a measure of smoking dependence. The State-Trait 
Anxiety Inventory (STAI), a self-report assessment device designed to 
measure participants’ subjective feelings of tension and apprehension. 
Carbon monoxide breath analysis performed using the Bedfont Micro 
Smokerlyser to verify participant smoking status, with readings above 
6 ppm confirming that the participant is a smoker. DSM IV structured 
questionnaire, to measure Nicotine withdrawal symptoms and cravings. 
A participant self-report diary was used to monitor adverse events 
and the number of cigarettes smoked during the quit period, with 
quitting rate expressed as the percentage of participants with confirmed 
abstinence. To help increase compliance, participants were asked to 
email or post the self-report diary to Swinburne University on a weekly 
basis. During the first 4 weeks of the trial (4 weeks pre-quit date) 
participants randomized to the HP group were required to start taking 
the recommended HP dose, for 28 days prior to the quitting smoking. 
Visit 2: Quit date (Week 4). On the quit date all participants were 
asked to continue taking these treatments for the remaining treatment 
duration period. Participants in the NRT treatment groups (groups 
2&3) commenced treatment with 21 mg dose patches for 6 weeks. 
Visit 3: 6 weeks post quit date (Week 10): On the third visit 
participants in the NRT group ceased taking the 21 mg treatment dose 
and commenced the 14 mg patch dosage for 2 weeks, followed by the 
final step down process of 7 mg patches per day for the final 2 weeks of 
the treatment period. The trial was then continued for a further 4 weeks 
with a fourth testing session conducted at week 14 (10 weeks post quit 
date) of the trial using the same tests. 
Visit 4: 10 weeks post-quit (Week 14). Participants from all three 
groups discontinued treatment and visited the BSI for follow up testing.
Statistical analysis
For the primary outcome variables non-parametric tests were used 
to assess differences in the number of smokers at week 14 identified 
by the Bedfont CO measure. For the secondary measures, repeated 
measures parametric analysis of variance was used to examine both 
changes from week 4 to week 14 (Time) and differences in changes in 
the measures from week to 14 that may differ between the groups (Time 
by Treatment). 
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Results
Primary Outcome: Smoking status at week 14
Analysis of the number of current smokers as assessed by the 
Bedfont Smokerlyzer (6 ppm) was used as the primary outcome 
variable. A score of 1 denotes negative test (i.e. non-smoker with a 
Bedfont score of less than 6 ppm) and a score of 2 denotes a positive 
CO test (i.e. smoker with a Bedfont score of 6 or greater) (Table 1).
There was no statistical difference between the three groups in the 
number of smokers at either the quit date (week 4) or at the completion 
of the study (Week 14, 10 post-quit). For the assessment of smoking 
status at week 4 all participants were smokers according to the Bedfont 
CO values. Using non-parametric statistics to assess differences in the 
number of smokers at the end of the treatment date-week 14 (10 weeks 
after the quit date) no statistically significant differences between the 
groups were found (Kruskal Wallis Independent samples test=.483 
df=2, p>.785). 
Secondary outcome variables
We also examined data for the STAI (state anxiety), DSM criteria & 
Fagerström dependence measures for both the factors of time (changes 
in scores between the quit date and week 14 (completion of the 
treatment) as well as time by treatment factor (changes in time between 
the three groups). The mean and SDs for these variables are presented 
in Table 2. 
Fagerström Tolerance was found to be significantly reduced at 
10 weeks following the quit date across treatment groups F=22.7, 
P<.001, although the treatment×time interaction was found to be 
non-significant F=1.8 NS. Fagerström Dependence was found to be 
significantly increased at 10 weeks following the quit date F=12.8, 
P<.001, with the treatment×time interaction also non-significant F=.72 
NS. Fagerström Craving was found to be significantly reduced at 10 
weeks following the quit date across treatment groups F=25.9, P<.001, 
and the treatment×time interaction was also found to be significant 
F=5.5, p<.01. Fagerström Relapse (positive) was found to be significantly 
increased at 10 weeks following the quit date F=19.3, P<.001, with the 
treatment ×time interaction non-significant F=1.4 NS. Fagerström 
Relapse (negative) was found to be significantly increased at 10 weeks 
following the quit date F=32.0, P<.001, with the treatment×time 
interaction non-significant F=2.3 NS. State Anxiety was now found to 
be significantly changed at 10 weeks following the quit date F=.38, NS, 
and neither was the treatment×time interaction significant F=.86 NS. 
Discussion
The finding of no significant differences between groups in the 
numbers of smokers at 10 weeks following the quit date indicates that 
each treatment condition was equally effective in smoking cessation as 
measured by CO criteria of 6 ppm. Interestingly there is a small trend 
that is suggestive of the combined treatment condition working best 
but this would only reach statistical significance in a much larger trial. 
Additionally future research should also use urinary measures to assess 
abstinence. Compared to urinary cotinine, CO has a shorter half-life and 
therefore the rate of false negative classifications using CO measurements 
may be higher. This will have implications for participation rates as well 
as costs in future studies but urinary measures provide the strongest 
evidence of abstinence. Nevertheless, CO measurements have been 
used previously in all of the HP smoking cessation studies and provide 
an efficient and consistent measure in which to interpret the findings of 
the current study within the background of previous studies. 
Given the equivalence of our primary measure between treatment 
groups, an analysis of the secondary measures was helpful in revealing 
potential differences between treatments in the context of smoking 
cessation.There was a significant time interaction for all variables 
except state anxiety. This suggests that across all three interventions 
(HP, NRT and combined HP/NRT) there were significant changes in 
our secondary measures except for state anxiety. These changes were 
in the expected direction based on previous studies indicating that 
feelings of dependence generally increased and tolerance decreased 
over the course of the intervention. In terms of the differential effects 
of the treatments, there were no significant differences in the time by 
treatment effects for all of our secondary variables except for craving. 
For this variable the HP treatment was best at reducing feelings of 
craving and this is consistent with the known pharmacological action of 
HP as well as previous research which has shown reductions in craving 
after HP administration [42]. Reducing craving may be an important 
factor in smoking cessation for many smokers and this mechanism 
may help explain the equivalence in cessation across the three different 
treatments arms observed in the present study. Clearly there are other 
mechanisms independent of craving that can be attributable to the 
efficacy of NRT observed in the current study.
There were some important components to the present trial. First, 
this was the first trial to examine this particular HP extract (Ze117) 
on smoking cessation. Ze117 is a high quality well-researched HP 
extract that has proven consistency, potency and quality. Another 
important component to this trial was that it included for the first 
time a combined HP/NRT arm. Given the different pharmacological 
actions of HP and NRT it could have been reasonably expected that the 
Visit 2 Quit date Visit 4 10 weeks post quit
(SDs) (SDs)
Ze117 group 1.27 (.46) 1.60 (.50)
Nicotine patches (NRT) 
group
1.18 (.39) 1.60 (.51)
Ze117/NRT group 1.00 (.00) 1.52 (.51)
Table 1: Mean number of participants classified as smokers at quite date and 10 
weeks after treatment based on CO value of 6ppm (1=non-smoker-less than 6 
ppm; 2=smoker 6 ppm or greater).
Variable Group Week 4
(quit date)
Week 14
(10 weeks post quit)
Mean SD Mean SD
Tolerance Ze117 4.0 3.0 2.8 2.2
NRT 5.1 2.3 1.6 2.8
Ze117/NRT 4.8 2.6 2.4 2.4
Dependence Ze117 1.6 .49 1.9 .26
NRT 1.6 .47 1.9 .25
Ze117/NRT 1.8 .39 1.9 .24
Craving Ze117 4.6 1.1 4.7 1.5
NRT 4.5 0.6 6.3 1.5
Ze117/NRT 3.5 1.1 5.3 1.6
Relapse-Positive Ze117 16.6 3.1 18.0 3.8
NRT 17.8 3.3 21.5 3.3
Ze117/NRT 17.1 3.4 19.4 4.4
Relapse-Negative Ze117 14.4 3.5 17.4 5.3
NRT 14.4 3.5 21.5 2.5
Ze117/NRT 12.4 3.5 16.7 5.6
State Anxiety Ze117 33.3 7.3 34.9 6.9
NRT 34.7 7.2 32.1 10.6
Ze117/NRT 36.5 9.1 35.1 12.1
Table 2: Means, SDs for secondary outcome variables at week 4 (quite date) and 
week 14 (10 weeks of treatment). 
Citation: Stough C, Scholey A, Kure C, Tarasuik J, Kras M, et al. (2013) An Open Label Study investigating the Efficacy of Hypericum perforatum 
Special Extract (ZE117), Nicotine Patches and Combination (ZE117)/Nicotine Patches for Smoking Cessation. Altern Integ Med 2: 147. 
doi:10.4172/2327-5162.1000147
Page 6 of 7
Volume 2 • Issue 9 • 1000147
Altern Integ Med
ISSN: 2327-5162  AIM, an open access journal 
combination treatment would show greater effect in terms of smoking 
cessation than either intervention alone. This was not the case. In fact 
the only significantly different effect observed in the current study was 
the significant decrease in symptoms of craving observed in the Ze117 
treatment arm.
The purpose of this study was to examine whether there was 
preliminary evidence for Ze117 rather than HP in general as a treatment 
option for smoking cessation. To adequately examine the efficacy 
of HP as a treatment option for smoking cessation a study in which 
several different HP extracts would need to be compared for smoking 
cessation. Therefore the results of this study can only generalise in terms 
of the specific HP extract used in the current study. As such there is 
now preliminary evidence justifying a considerably larger randomized 
double blind study administering this particular HP extract (Ze117) for 
smoking cessation. Data from this large study if confirming the pilot 
data could lead to the use of Ze117 for smoking cessation in addition 
to NRT. 
The smoking cessation market is currently a multi-billion dollar 
industry and many smokers fail to give up smoking after NRT treatment. 
Additionally NRT and other treatments show a considerably higher 
side-effect profile than HP in general and Ze117 specifically. Increasing 
choice of treatments may have important consequences for reducing 
the burden of smoking related diseases in many countries. Future 
studies should also employ more mechanistic measures and examine 
interactions between nicotine and Ze117 for cytochrome enzymes (i.e. 
safety data). Given the significant health effects of smoking, alternative 
treatments for smoking cessation are urgently required. The results of 
this study, although preliminary provide a strong framework for larger 
efficacy and safety studies.
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